Navigation Links
Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
Date:5/16/2010

ts to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings growth is not a profit forecast and should not be interpreted to mean that Astellas' earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Astellas.


'/>"/>
SOURCE Astellas Pharma US, Inc.; OSI Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
2. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
3. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
4. CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
5. Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)
6. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
7. CV Therapeutics Statement on Unsolicited Proposal From Astellas
8. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
9. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
10. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
11. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
(Date:7/10/2014)... 2014 -- According to the International Atomic Energy ... comes from terrorists acquiring sufficient quantities of plutonium ... crude nuclear explosive device. The IAEA also notes ... involved gram-level quantities, which can be challenging to ... a new study appearing this week in the ...
(Date:7/10/2014)... the journal PNAS (Proceedings of the National Academy ... and sleep deprivation have a significant effect on our ... the best time of day to test for diseases ... medicines effectively. , Researchers from the University of Surrey ... links between sleep deprivation, body clock disruption and metabolism, ...
(Date:7/10/2014)... The lithium-ion batteries that power our laptops and electric ... a single charge with the help of a sponge-like ... to replace the graphite traditionally used in one of ... times the energy storage capacity of graphite. A paper ... was published today in Nature Communications . , ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2Time of day crucial to accurately test for diseases, new research finds 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... SuperGen Inc.,(Nasdaq: SUPG ), a pharmaceutical company ... therapies for solid tumors and,hematological malignancies, today announced ... Officer is scheduled to present at the Thomas,Weisel ... the Four,Seasons Hotel in Boston. SuperGen,s presentation ...
... Aug. 29 Caliper Life,Sciences, Inc. (Nasdaq: ... the,Thomas Weisel Partners Healthcare Conference 2007 will be ... Kevin Hrusovsky, President and CEO,of Caliper, will be ... http://www.veracast.com/webcasts/twp/healthcare07/98209449.cfm . An archived,presentation will be available for ...
... Aug. 28 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS, Nasdaq: PXSL) ... of,Bronchitol for the treatment of people with bronchiectasis ... life and mucus clearance. Data from the ... quality of life after 12 weeks of treatment ...
Cached Biology Technology:Phase III Trial Finds Pharmaxis' Bronchitol Effective 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 3
(Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
(Date:7/11/2014)... -- Research and Markets has announced the ... Industry Analysis Size Share Growth Trends and Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 The rising number ... for high level security in both private and public ... username and passwords, tokens etc. are vulnerable to attacks. ...
(Date:7/10/2014)... Albuquerque, and other major cities in New Mexico, nearly ... municipal wastewater rather than precious potable water supplies. Across ... of all golf courses receive treated effluent. Reusing the ... Additionally, golf courses and homeowners alike fertilize their lawns ... is nitrate. A New Mexico State University turfgrass expert ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2'Tailored' water -- the latest in lawn care 2
... is available in French . Montreal -- ... consumers, thanks to Concordia University researchers who,ve developed a new ... products. "Even though Canada does not allow the use ... there were no methods or equipment to effectively measure residual ...
... With concerns about jobs in the headlines around the world, ... ( C&EN ) presents a 3-part cover story on the ... than 96% of all manufactured goods, with the chemical industry ... C&EN is the weekly newsmagazine of the American Chemical ...
... and BGI, the world,s largest genomics institute, today ... conduct large-scale human genome sequencing and bioinformatics analysis ... at Children,s Hospital. The partnership will focus on ... pediatric diseases using next-generation sequencing. The Center became ...
Cached Biology News:Children's Hospital of Philadelphia and BGI announce partnership and new Joint Genome Center 2
Yersinia pestis...
... WinList come straight from the folks who ... automatic region positioning, N-Stat regions, and presentation-quality ... thoughtful conversations, and careful design. Of course, ... are still there, too. WinList leads the ...
Insect Cell Lysis Buffer 50 ml...
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Biology Products: